The present invention is for screening for substances that selectively inhibit binding between DDX3 proteins and HBV polymerase as distinct from the molecules of the virus itself, and it can be expected that not only will there be only a very remote possibility of mutant viruses occurring that have resistance to avoid the same but also that the cytotoxicity with respect to host cells will be extremely low since the invention entails a target that is formed specifically only in infected cells. In particular, there is the advantage that the invention is outstanding in terms of cytotoxicity and the low occurrence of resistant mutations in chronic hepatitis B requiring long-term treatment of 1 year or more.La présente invention concerne le criblage de substances qui inhibent sélectivement la liaison entre des protéines DDX3 et la polymérase de VHB de façon distincte par rapport aux molécules du virus lui-même, et il peut être attendu que non seulement il y ait une probabilité très faible de loccurrence de virus mutants qui ont une résistance pour éviter cela mais également que la cytotoxicité vis-à-vis des cellules hôtes soit extrêmement faible étant donné que linvention concerne une cible qui est formée spécifiquement uniquement dans des cellules infectées. En particulier, il existe un avantage en ce que linvention est excellente en termes de cytotoxicité et de faible occurrence de mutations résistantes dans lhépatite B chronique nécessitant un traitement à long terme de 1 an ou plus.본 발명은 바이러스 분자 자체가 아닌 HBV 폴리머라제-DDX3 단백질간의 결합을 선택적으로 저해하는 물질을 스크리닝하는 것이므로 이를 회피하기 위한 내성을 갖는 돌연변이 바이러스의 발생 가능성이 매우 희박할 뿐 아니라 감염세포에만 특이적으로 형성된 표적본이므로 숙주세포에 대한 세포독성이 극히 낮을 것으로 기대된다. 특히 1년 이상 장기 치료를 요하는 만성 B형 간염의 경우 낮은 내성돌연변이 발생 및 세포독성은 현저하게 뛰어난 장점을 가진다.
